Jan smith
Company: Revolution Medicines
Job title: Chief Scientific Officer, Senior Vice President & Head Of Biology
Seminars:
Targeting Beyond G12C in RAS-Addicted Cancers: Opportunities Using RAS(ON) TriComplex Inhibitors 11:45 am
day: Day One Track B AM